Censa Pharmaceuticals

@CensaPharma

Developing an oral, first-line therapy for phenylketonuria (PKU) patients of all ages and disease severity.

Wellesley, MA
Vrijeme pridruživanja: studeni 2019.

Tweetovi

Blokirali ste korisnika/cu @CensaPharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CensaPharma

  1. proslijedio/la je Tweet
    5. pro 2019.

    “There is a significant unmet need for an oral therapy that is effective in both mild and severe PKU patients.” Censa Pharmacueticals sees positive results in phase 2 trial for its experimental medicine for the treatment of .

    Poništi
  2. 4. pro 2019.

    Before 5:00p tomorrow (12/5), help make Censa the Buzz of the BIO CEO & Investor Conference by taking a minute to vote for us in the private therapeutic biotech category:

    Poništi
  3. 3. pro 2019.

    Censa Pharmaceuticals Announces CNSA-001 Met Primary and Secondary Endpoints in Phase 2 Trial in Patients with (PKU).

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·